CYP11A1 Drug Discovery Landscape & Assay Solutions

  • By admin
  • 06 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Steroidogenesis Inhibition and Hormone-Dependent Cancer Therapy.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for CYP11A1 (P450scc) drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen CYP11A1 Recombinant Protein (Mitochondrial)
Full-length with transit peptide or catalytic domain. Sequence Verified, >95% Purity (SDS-PAGE), Endotoxin <1EU/µg. Suitable for enzyme kinetics.		 View CYP11A1 Products
Gene Delivery CYP11A1 Lentivirus Premade Particles
CMV/EF1a promoter with mito-targeting sequence. For stable cell line construction in H295R or HEK293 backgrounds.		 View CYP11A1 Products
Benchmark Ab Anti-CYP11A1 Polyclonal/Monoclonal
For Western Blot and IHC validation of target engagement in adrenal/gonadal tissue sections.		 View CYP11A1 Products
Validator CYP11A1 siRNA Set (3 target-specific sequences)
For knockout validation in steroidogenic cell models. Sequence Verified, HPLC purified.		 View CYP11A1 Products
Selectivity Panel CYP17A1 (17α-Hydroxylase)
Critical off-target for steroid synthesis pathway selectivity screening.		 View CYP17A1 Products
Selectivity Panel CYP11B1 (11β-Hydroxylase)
Mitochondrial CYP family member with high homology; essential for counter-screening.		 View CYP11B1 Products
Upstream Regulator STAR (Steroidogenic Acute Regulatory Protein)
Cholesterol shuttle protein controlling CYP11A1 substrate availability; compensatory resistance mechanism target.		 View STAR Products
Pathway Partner AR (Androgen Receptor)
Synergistic pathway target for castration-resistant prostate cancer (CRPC) combinations; resistance-associated.		 View AR Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
Mitochondrial Membrane Integration & Conformation Native HEK293 Expression with Mito-Targeting Sequence; preserves N-terminal transit peptide for proper membrane insertion. Alternative: E. coli expressed catalytic domain with refolding protocols.
Electron Transport System Requirement Co-expression systems available. Adrenodoxin (FDX1) and Adrenodoxin Reductase (FDXR) companion proteins provided for functional reconstitution.
CYP Family Selectivity (CYP11B1/B2 vs CYP11A1) Ortholog panel including CYP11B1 and CYP11B2 proteins with >95% purity for cross-reactivity assessment; Mass Spec verified identity.
Cell-Based Functional Validation Pregnenolone detection assay ready: Lentivirus-transduced stable lines in H295R background with steroidogenic capacity.
Compound Mitochondrial Permeability Whole-cell assay formats using TarMart stable cell lines; discriminate membrane permeability from intrinsic enzyme inhibition.
Active Site Mutations Recombinant variants (e.g., R96W, L437P) available for resistance profiling; sequence verified.

Live CYP11A1 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The therapeutic targeting of CYP11A1 (P450scc) represents a strategic pivot toward "upstream blockade" of steroidogenesis. Unlike CYP17 or aromatase inhibitors that block specific steroid branches, CYP11A1 inhibition halts all steroid hormone synthesis at the cholesterol-to-pregnenolone conversion step. Current R&D focuses heavily on triple-negative breast cancer (TNBC), Cushing's syndrome, and castration-resistant prostate cancer (CRPC). In CRPC, resistance to first-generation CYP17A1 inhibitors (e.g., abiraterone) arises from alternative androgen synthesis pathways and AR mutations, driving the need for complete upstream blockade. The most advanced clinical compound is ODM-208 (MK-5684) from Orion Corporation/MSD, an oral highly selective CYP11A1 inhibitor currently in Phase II/III for mCRPC. The field is transitioning from non-selective azole antifungals (ketoconazole) to highly specific inhibitors with optimized mitochondrial permeability. As first-wave compounds advance, critical differentiators include selectivity over hepatic CYPs, adrenal CYP11B enzymes, and the ability to maintain efficacy in the presence of tumor-associated CYP11A1 variants.

Key Genetic Variations & Resistance Mechanisms

Several naturally occurring mutations in CYP11A1 have been characterized in the context of autoimmune polyendocrine syndrome type I (APS1) and other disorders. Key mutations include R96W (dbSNP: rs121912813), which shows reduced activity, and L437P (dbSNP: rs387906601), which exhibits markedly reduced activity. A non-pathogenic variant R120W (dbSNP: rs121912811) shows no loss of activity. These mutations may impact inhibitor binding and contribute to emerging resistance. Additionally, compensatory upregulation of STAR (steroidogenic acute regulatory protein) can increase cholesterol substrate delivery to mitochondria, partially bypassing CYP11A1 inhibition. Understanding these resistance mechanisms is crucial for developing next-generation inhibitors and combination strategies.

Competitive Modality & Indication Snapshot

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Small Molecule Inhibitor Academic consortia, Oncoceutics (OV501), Orion Corporation/MSD (ODM-208) Cushing's Syndrome, TNBC, Prostate Cancer (incl. mCRPC) Enzyme Kinetics (Need purified CYP11A1 + redox partners); Selectivity vs CYP11B1/CYP11B2
siRNA / Gene Silencing Arrowhead, Alnylam (exploratory) Adrenal Disorders Target Engagement (Need CYP11A1 protein standards for ELISA/Western quantification)
PROTAC Degrader Emerging Biotechs Steroid-Dependent Tumors Cell-Based Degradation Assay (Need Lentivirus-stable lines with tagged CYP11A1)
Gene Therapy / Replacement Academic/Rare Disease Congenital Adrenal Hyperplasia Expression Validation (Need Lentivirus and Benchmark Abs)
ADC (Targeted Delivery) Not applicable N/A Intracellular target; cell-based delivery validation using TarMart siRNA controls